Sable Bio: AI drug safety and Seed from MMC Ventures

Introduction: AI-powered drug safety and opportunities for VCs

The London-based startup Sable Bio announces €3.15 million seed to grow its AI platform dedicated to drug safety. The round is led by MMC Ventures with participation from Episode 1 Ventures and Seedcamp. This operation underscores the growing interest in AI applications in pharmaceutical risk management.

The context and Sable Bio’s approach

Founded in 2023 by former BenevolentAI scientists, Sable Bio is developing a platform that provides predictive safety insights to mitigate the risk of failure in clinical trials. The company explains that the rising volume of biomedical data requires tools that integrate heterogeneous sources to define reliable risk signals. The platform combines data from diverse sources to provide concrete safety insights.

Dr Josh Almond-Thynne, co-founder and CEO: Drug target safety requires complete, accessible data; with this round we can build the ultimate platform for drug safety

In 2024 they announced commercial agreements with three of the world’s leading pharmaceutical companies, along with biotech and investors, and logged over €400k in revenue in the past year. The aim is to accelerate development and close new partnerships to expand the portfolio.

In February 2024, Sable Bio closed a pre-seed round of €1.7 million, supported by Episode1 Ventures and Seedcamp.

Nitish Malhotra, MMC Ventures: Drug safety remains one of the major R&D challenges; Sable is building a safety intelligence platform that pharma teams are already using

Sable Bio’s vision is to offer predictive insights that enable informed decisions across the full development lifecycle, integrating data from literature, clinical trials, and real-world evidence. The platform aims to translate large volumes of data into operational signals for research teams.

SOURCE: Founders and investors describe the mission to build a drug-safety platform supporting multiple stages of discovery

The capital will be used to expand the team, accelerate product development, and seek additional partnerships with biotech and pharma companies. The strategy is to grow the London team and accelerate product development.

Discussion and reflections on AI’s impact on pharmaceutical safety

The debate centers on how much AI can accelerate drug safety without compromising interpretability, privacy, and regulatory compliance. On one hand, Sable’s approach promises rapid insights, cost reductions, and data-driven R&D decisions; on the other, there are risks related to false signals, bias, and reliance on heterogeneous sources. The real promise lies in integrating heterogeneous data and extracting reliable signals to guide clinical decisions. Some experts push for validation and transparency standards, calling for collaboration with regulators and academic labs to ensure models are trustworthy. Some argue adoption requires tangible use cases: pilot projects with evidence of improved success rates or risk management. In any case, attention to data governance, model auditing, and independent verification will be crucial. Finally, the question remains whether AI can fully replace traditional safety assessment pipelines or mainly serve as an advanced complement.

In conclusion, adopting solutions like Sable Bio depends on balancing speed, reliability, and compliance. Companies that demonstrate transparency, validation, and tangible results will be more likely to drive real transformation in the drug discovery and development process.

Source eu-startups.com